Abbreviation | Full description |
---|---|
Histologically diagnosable liver lesions | |
Neoplasms | epithelial neoplasms (liver cell adenoma, cholangioma, hepatocellular carcinoma, cholangiocellular carcinoma, mixed hepatobiliary carcinoma, biliary cystadenoma, biliary cystadenocarcinoma, pancreatic acinar cell adenoma, pancreatic ductal adenoma, pancreatic cystadenoma, pancreatic acinar cell carcinoma, pancreatic adenocarcinoma); and mesenchymal neoplasms (hemangioma, hemangioendothelioma, hemangioentothelial sarcoma, fibroma, fibrosarcoma, hemangiopericytoma, neurilemmoma, neurofibroma, neurofibrosarcoma |
Foci of cellular alteration (FCA) | putative preneoplastic focal lesions (foci of cellular alteration, including clear cell focus, eosinophilic focus, basophilic cell focus, and hyperplastic hepatocellular regeneration) |
Proliferative lesions | proliferative non-neoplastic lesions (hepatocellular or biliary regeneration, biliary hyperplasia, papillary biliary hyperplasia, cystic biliary hyperplasia, cholangiofibrosis/adenofibrosis, increased hepatocellular mitotic activity) |
Hydropic vacuolation | hepatocellular or biliary hydropic vacuolation (syn RAM cell areas, atypical cellular vacuolation) |
Spongiosis hepatis | spongiosis hepatis or cystic degeneration of hepatocellular parenchyma |
Megalocytic hepatosis/nuclear pleomorphism | increased hepatocellular and nuclear diameter and nuclear nyperchromasia, often accompanied by cytoplasmic changes including hyalinization (megalocytic hepatosis); enlarged or pleomorphic hepatocellular nuclei, unaccompanied by changes in hepatocellular size (nuclear pleomorphism) |
Necrotic lesions | nonspecific hepatocellular or biliary necrotic/degenerative conditions including coagulative necrosis, hydropic degeneration, hyalinization, liquefactive necrosis, pyknosis, karyorrhexis, eosinophilic change, and hemorrhagic necrosis |
Histologically diagnosable kidney lesions | |
Proliferative lesions | non-neoplastic proliferative lesions, including hemopoietic tissue hyperplasia or proliferation, eruythroblastic hyperplasia or proliferation, glomerular hypercullularity, thickened, proliferative Bowman's capsule, tubular hyperplasia or proliferation, increased mitotic activity of tubules or hemopoietic tissue, and tubular regeneration |
Necrotic lesions | necrotic lesions, including mesangiolysis, glomerular degeneration, tubular necrosis/degeneration, coagulative necrosis, hyalinization, or hydropic degeneration or tubular epithelium, hemopoietic tissue atrophy or hypoplasia, degeneration of Bowman's capsule, glomerular hyalinization, microvacuolar degeneration of tubular epithelium, erythrocyte necrosis of hemopoietic tissue, exfoliation of tubular epithelium, pyknosis of tubular epithelium or other nephron elements, cellular debris in tubular lumina, atypical cytoplasmic vacuolation of tubular epithelium or other nephron elements |
Sclerotic lesions | sclerotic lesions including mesangiosclerosis, hypermembranous tubules (thickened basal lamina), hypermembranous glomerular tuft (thickened peripheral basal lamina), calcification, glomerulosclerosis, peritubular fibrosis, and fibrosis/fibroplasia of the interstitium |
Grossly diagnosable lesions | |
Fin erosion | fin erosion and associated lesions, including loss of fin, hemorrhagic fin tissue, fused rays, bent fin, exposed fin rays, fin ray blunting or retraction, and reflection of fin tissue back onto body surface |
Type | Chemical |
---|---|
Low molecular weight aromatic hydrocarbons (LAHs) | naphthalene |
decachlorobiphenyls 2-methylnaphthalene | |
decachlorobiphenyls 1-methylnaphthalene | |
decachlorobiphenyls biphenyl | |
decachlorobiphenyls 2,6-dimethylnaphthalene | |
decachlorobiphenyls acenapthene | |
decachlorobiphenyls acenapthylene | |
decachlorobiphenyls 2,3,5-trimethylnaphthalene | |
decachlorobiphenyls fluorene | |
decachlorobiphenyls phenanthrene | |
decachlorobiphenyls anthracene | |
decachlorobiphenyls 1-methylphenanthrene | |
High molecular weight aromatic hydrocarbons (HAHs) | fluoranthene |
decachlorobiphenyls pyrene | |
decachlorobiphenyls benz[a]anthracene | |
decachlorobiphenyls chrysene | |
decachlorobiphenyls benzo[b]fluoranthene | |
decachlorobiphenyls benzo[k]fluoranthene | |
decachlorobiphenyls benzo[e]pyrene | |
decachlorobiphenyls benzo[a]pyrene | |
decachlorobiphenyls perylene | |
decachlorobiphenyls ideno[1,2,3-cd]pyrene | |
decachlorobiphenyls dibenz[a,h]anthracene | |
decachlorobiphenyls benzo[ghi]perylene | |
DDTs | o,p'-DDE |
decachlorobiphenyls p,p'-DDE | |
decachlorobiphenyls o,p'-DDD | |
decachlorobiphenyls p,p'-DDD | |
decachlorobiphenyls o,p'-DDT | |
decachlorobiphenyls p,p'-DDT | |
PCBs | trichlorobiphenyls |
decachlorobiphenyls tetrachlorobiphenyls | |
decachlorobiphenyls pentachlorobiphenyls | |
decachlorobiphenyls hexachlorobiphenyls | |
decachlorobiphenyls heptachlorobiphenyls | |
decachlorobiphenyls | |
decachlorobiphenyls | |
decachlorobiphenyls | |
Chlordanes | alpha-chlordane |
decachlorobiphenyls |
Total AHs | LAHs | HAHs | DDTs | PCBs | Chlordanes | |
---|---|---|---|---|---|---|
Total AHs | 1 | 0.99 | 0.99 | 0.72 | 0.71 | 0.88 |
LAHs | 1 | 0.96 | 0.71 | 0.70 | 0.86 | |
HAHs | 1 | 0.74 | 0.71 | 0.88 | ||
DDTs | 1 | 0.79 | 0.87 | |||
PCBs | 1 | 0.82 | ||||
Chlordanes | 1 |
Chemical class |
Sediment vs. stomach contents |
Stomach contents vs. tissue or bile |
Sediment vs. tissue or bile |
---|---|---|---|
LAHs (n=24) | 0.82 | 0.56 (BaP), 0.79 (NPH) | 0.52 (BaP), 0.72 (NPH) |
HAHs (n=24) | 0.78 | 0.53 (BaP), 0.65 (NPH) | 0.45 (BaP), 0.68 (NPH) |
Total AHs (n=24) | 0.84 | 0.55 (BaP), 0.70 (NPH) | 0.48 (BaP), 0.69 (NPH) |
DDTs (n=24) | 0.43 | 0.83 | 0.21 |
PCBs (n=24) | 0.58 | 0.76 | 0.50 |
Chlordanes (n=24) | 0.48 | 0.77 | 0.37 |
Lesion | Risk factor | Odds ratio |
---|---|---|
Hepatic lesions | ||
Neoplasms GM = 5.773E-04 |
Age | .1928 |
Female | 21.46 | |
Raritan Bay, Gravesend | 3.887 | |
Boston Harbor, Deer Island | 8.973 | |
Raritan Bay, West Reach | 5.081 | |
Boston Harbor, Hull Bay | 1.988 | |
Foci of cellular alteration GM = 2.572E-03 |
Age | 1.373 |
Raritan Bay, Gravesend | 7.708 | |
Boston Harbor, Deer Island | 3.500 | |
Boston Harbor, Mystic River | 4.368 | |
Buzzards Bay | 3.828 | |
Proliferative lesions GM = 1.275E-03 |
Age | 1.673 |
Boston Harbor, Deer Island | 3.939 | |
Boston Harbor, Mystic River | 1.673 | |
Cystic degeneration GM = 3.837E-02 |
Age | 2.244 |
Boston Harbor, President Roads | 13.06 | |
Female | 0.1582 | |
Nuclear pleomorphism GM = 1.463E-02 |
Long Island Sound, New Haven | 4.883 |
Hydropic vacuolation GM = 2.940E-01 |
Age | 1.345 |
Boston Harbor, Mystic River | 10.56 | |
Raritan Bay, East Reach | 6.594 | |
Boston Harbor, Deer Island | 5.403 | |
Long Island Sound, Norwalk | 6.752 | |
Long Island Sound, New Haven | 5.620 | |
Raritan Bay, Gravesend | 8.962 | |
Salem Harbor, Folgers Point | 2.481 | |
Boston Harbor, President Roads | 4.336 | |
Boston Harbor, Hull Bay | 3.875 | |
Boston Harbor, Quincy Bay | 4.387 | |
Necrosis GM = 4.681E-02 |
Age | 1.184 |
Boston Harbor, Mystic River | 2.176 | |
Boston Harbor, Hull Bay | 2.010 | |
Boston Harbor, Quincy Bay | 3.258 | |
Boston Harbor, President Roads | 2.607 | |
Raritan Bay, West Reach | 2.826 | |
Kidney lesions | ||
Proliferative lesions GM = 1.838E-03 |
Salem Harbor, Folgers Point | 9.143 |
Buzzard Bay | 9.067 | |
Necrotic lesions GM = 3.566E-03 |
Age | 1.786 |
Boston Harbor, Deer Island | 10.04 | |
Female | 0.2252 | |
Sclerotic lesions GM = 1.28E-03 |
Age | 1.839 |
Long Island Sound, New Haven | 4.331 | |
Niantic Bay, Black Point | 4.831 | |
Fin lesions | ||
Fin erosion GM = 1.489E-02 |
Age | 1.379 |
Boston Harbor, Mystic River | 8.690 | |
Long Island Sound, New Haven | 11.89 | |
Boston Harbor, Deer Island | 2.884 | |
Boston Harbor, Quincy Bay | 3.547 | |
Long Island Sound, Norwalk | 3.752 | |
Niantic Bay, Black Point | 2.505 |
Hydropic vacuolation | Necrotic lesions | ||||
---|---|---|---|---|---|
Site name | Spring | Winter | Spring | Winter | |
Massachusetts Bay, Plymouth Entrance | 0% (n=25) | 0% (n=22) |
16% (n=25) | 5% (n=22) |
|
Narragansett Bay, Prudence Island | 4% (n=51) | 10% (n=39) |
2% (n=51) | 3% (n=39) |
|
Boston Harbor, Deer Island | 47% (n=100) | 11%* (n=27) |
10% (n=100) | 0%* (n=27) |
|
Boston Harbor, Mystic River | 59% (n=37) | 20%* (n=30) |
27% (n=37) | 30% (n=30) |
|
Niantic Bay, Black Point | 20% (n=81) | 4%* (n=69) |
6% (n=81) | 0%* (n=69) |
|
Total | 30% (n=294) | 9%* (n=187) |
10% (n=294) | 6%* (n=187) |
Chemical* class |
n |
Proliferative lesions |
Necrotic lesions |
Sclerotic lesions |
Fin erosion |
---|---|---|---|---|---|
LAHs | 24 | ns | ns | ns | (+) p=0.001 14% |
HAHs | 24 | ns | ns | ns | (+) p=0.001 15% |
Total AHs | 24 | ns | ns | ns | (+) p=0.001 15% |
DDTs | 24 | ns | ns | ns | (+) p=0.025 3% |
PCBs | 24 | ns | ns | ns | ns |
Chlordanes | 24 | ns | ns | ns | (+) p=0.001 14% |
Chemical* class |
n |
Proliferative lesions |
Necrotic lesions |
Sclerotic lesions |
Fin erosion |
---|---|---|---|---|---|
LAHs | 24 | ns | (+) p=0.05 11% | ns | (+) p=0.001 15% |
HAHs | 24 | ns | ns | ns | (+) p=0.014 5% |
Total AHs | 24 | ns | ns | ns | (+) p=0.004 5% |
DDTs | 24 | ns | ns | ns | (+) p=0.025 3% |
PCBs | 24 | ns | ns | ns | ns |
Chlordanes | 24 | ns | ns | ns | (+) p=0.007 16% |
Chemical* class |
n |
Proliferative lesions |
Necrotic lesions |
Sclerotic lesions |
Fin erosion |
---|---|---|---|---|---|
Bile FACs-H | 24 | ns | ns | ns | (+) p=0.001 7% |
Bile FACs-L | 24 | ns | ns | ns | (+) p=0.001 9% |
DDTs | 24 | ns | ns | ns | ns |
PCBs | 24 | ns | ns | ns | ns |
Chlordanes | 24 | ns | ns | ns | ns |